Ascendis Pharma
Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
Inga nordiska FDA-avslag gällde kliniska data
FDA har under 2026 godkänt läkemedel från bland...
Bioteknik
Oncopeptides rides the CHMP wave, AstraZeneca adds eight more years – the Nordic Pulse | 2026:38
Consensus Analysis | Ascendis Pharma | 2026-09-14
AstraZeneca’s hat-trick, a broad sell-off and Alzinova funds its Alzheimer’s push – the Nordic Pulse | 2026:37
AstraZeneca strikes again, BioArctic’s Leqembi goes global and Cinclus holds its breath – the Nordic Pulse | 2026:36
BioArctic’s home-run, a third win for Astra’s Tezspire and a path to phase III for Lytix – the Nordic Pulse | 2026:35
Demant raises the bar, XVIVO clears hearts and Zealand cashes in – the Nordic Pulse | 2026:33
Novo raises outlook, BioInvent breaks through, Nordics tread water – the Nordic Pulse | 2026:32
Hansa closes, AlzeCure soars, Ascelia falters – the Nordic Pulse | 2026:27
Analytics
